Compare DexCom, Inc. (DXCM) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JPMorgan Chase & Co — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while JPMorgan Chase & Co trades at $332.99 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 27.7× DexCom, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.99% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and JPMorgan Chase & Co for 127 Days on average.
| DXCM | JPM | |
|---|---|---|
Market Cap | $31.86B | $880.98B |
Volume | 3,607,070 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $92.34 | $365.18 |
52-Week Low | $54.84 | $282.84 |
Typical Hold Time | 62 Days | 127 Days |
Enterprise Value | $31.32B | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
JPMorgan Chase (JPM) trades at $331.42, up 0.56% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but missed Q4 2025 expectations. Revenue grew to $181.85B in 2025 with solid profitability metrics including 33.38% net income margin and 18.43% ROE. Analyst consensus remains positive with 52.46% buy ratings and $373.18 price target representing 12.6% upside potential.
JPMorgan demonstrates fundamental strength with consistent revenue growth and industry-leading profitability, though negative cash flow trends and geopolitical risks warrant monitoring. The stock offers value at 14.2 P/E with institutional support, but investors should weigh macroeconomic uncertainties and banking sector volatility against the company's strong market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
